Abstract:Protein aggregation is common to dozens of diseases including prionoses, diabetes, Parkinson’s and Alzheimer’s. Over the past 15 years, there has been a paradigm shift in understanding the structural basis for these proteinopathies. Precedent for this shift has come from investigation of soluble Aβ oligomers (AβOs), toxins now widely regarded as instigating neuron damage leading to Alzheimer’s dementia. Toxic AβOs accumulate in AD brain and constitute long-lived alternatives to the disease-defining Aβ fibrils deposited in amyloid plaques. Key experiments using fibril-free AβO solutions demonstrated that while Aβ is essential for memory loss, the fibrillar Aβ in amyloid deposits is not the agent. The AD-like cellular pathologies induced by AβOs suggest their impact provides a unifying mechanism for AD pathogenesis, explaining why early stage disease is specific for memory and accounting for major facets of AD neuropathology. Alternative ideas for triggering mechanisms are being actively investigated. Some research favors insertion of AβOs into membrane, while other evidence supports ligand-like accumulation at particular synapses. Over a dozen candidate toxin receptors have been proposed. AβO binding triggers a redistribution of critical synaptic proteins and induces hyperactivity in metabotropic and ionotropic glutamate receptors. This leads to Ca2+ overload and instigates major facets of AD neuropathology, including tau hyperphosphorylation, insulin resistance, oxidative stress, and synapse loss. Because different species of AβOs have been identified, a remaining question is which oligomer is the major pathogenic culprit. The possibility has been raised that more than one species plays a role. Despite some key unknowns, the clinical relevance of AβOs has been established, and new studies are beginning to point to co-morbidities such as diabetes and hypercholesterolemia as etiological factors. Because pathogenic AβOs appear early in the disease, they offer appealing targets for therapeutics and diagnostics. Promising therapeutic strategies include use of CNS insulin signaling enhancers to protect against the presence of toxins and elimination of the toxins through use of highly specific AβO antibodies. An AD-dependent accumulation of AβOs in CSF suggests their potential use as biomarkers and new AβO probes are opening the door to brain imaging. Overall, current evidence indicates that Aβ oligomers provide a substantive molecular basis for the cause, treatment and diagnosis of Alzheimer’s disease.

Intracellular A beta and its Pathological Role in Alzheimer's Disease: Lessons from the Cellular to Animal Model

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

The Role of Intracellular Amyloid Beta in Alzheimer'S Disease

Recent Progress in the Study of Intracellular Toxicity of Amyloid Beta Peptide in Alzheimer'S Disease

Recent Progress in the Study of Intracellular Toxicity of Amyloid Β Peptide in Alzheimer＇s Disease

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Impact of Alternating Amino Acid Sequences on Beta-Amyloid-induced Neurotoxicity and Neuroinflammation in Alzheimer's Disease.

The Recent Updates of Therapeutic Approaches Against Aβ for the Treatment of Alzheimer's Disease

Current strategies of detecting Aβ species and inhibiting Aβ aggregation: Status and prospects

The Amyloid-Beta Clearance: From Molecular Targets to Glial and Neural Cells

Physiological Roles of beta-amyloid in Regulating Synaptic Function: Implications for AD Pathophysiology

Advances in Understanding the Β-Amyloid Precursor Protein Intracellular Domain

Advances in the β-amyloid precursor protein of Alzheimer's disease

A Toxicogenic Interaction between Intracellular Amyloid-β and Apolipoprotein-E

Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease

Proteomic Analysis Reveals Physiological Activities of Aβ Peptide for Alzheimer's Disease

Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

An Updated Review of Amyloid Beta Oligomer Toxicity Inhibition and Detection for Alzheimer's Disease Diagnosis

Recent Developments in the Chemical Biology of Amyloid-Β Oligomer Targeting

Intraneuronal Alzheimer A Beta 42 Accumulates in Multivesicular Bodies and is Associated with Synaptic Pathology